Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

Entasis Therapeutics (NASDAQ: ETTX) has announced its participation in the virtual Wedbush PacGrow Healthcare Conference on August 10-11, 2021. Management will present on August 11 at 4:40 p.m. ET, discussing the company's focus on developing novel antibacterial therapies targeting multidrug-resistant Gram-negative bacteria.

Entasis' pipeline includes treatments for infections caused by Acinetobacter baumannii, Neisseria gonorrhoeae, Enterobacteriaceae, and Pseudomonas. The presentation will be accessible via their website.

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Wedbush PacGrow 2021 Virtual Healthcare Conference
Format: Panel presentation (Infectious Personality) and one-on-one investor meetings
Presentation Date & Time: Wednesday, August 11, 2021, at 4:40 p.m. ET

The webcast of the Wedbush presentation will be accessible in the News & Events section of the Entasis website at https://www.entasistx.com/.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Company Contact:         
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com

Investor Relations Contact:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
bmackle@lifesciadvisors.com

FAQ

When is Entasis Therapeutics presenting at the Wedbush PacGrow Healthcare Conference?

Entasis Therapeutics will present on August 11, 2021, at 4:40 p.m. ET.

What is the focus of Entasis Therapeutics?

Entasis Therapeutics focuses on the discovery and development of novel antibacterial products for serious infections caused by multidrug-resistant bacteria.

Where can I find the webcast of the Entasis presentation?

The webcast of the presentation will be available in the News & Events section on the Entasis website.

What are some of the products in Entasis Therapeutics' pipeline?

Entasis has product candidates targeting infections such as Acinetobacter baumannii, Neisseria gonorrhoeae, Enterobacteriaceae, and Pseudomonas.

Is the Wedbush PacGrow Healthcare Conference virtual?

Yes, the Wedbush PacGrow Healthcare Conference is being held virtually.